Report cover image

Global Liver Disease Market, Global Forecast 2023-2027, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis

Publisher Renub Research
Published Oct 01, 2022
Length 140 Pages
SKU # RNBR17480739

Description

Global Liver Disease Market, Global Forecast 2023-2027, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis

Liver Disease Market will reach US$ 26.30 Billion in 2027. In the human body, the liver is a vital organ that plays significant functions like storing vitamins and nutrients, maintaining an adequate balance of chemicals in the body, and removing harmful substances from the blood. Non-alcoholic Fatty Liver Disease, Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases.

As per the study “Burden of Liver Diseases in the World,” issued in 2019, globally, liver disorders account for about 2 million deaths per year, out of which 1 million are due to viral hepatocellular carcinoma, and hepatitis, as well as 1 million are owing to complications of cirrhosis. Cirrhosis is the 11th most common cause of death worldwide, and liver cancer is the 16th leading cause of death.

Liver Disease Market Size is likely to expand at a CAGR of 8.40 % during 2021 – 2027:

The liver disease treatment market will show rapid growth due to the rising government initiatives of providing vaccines, growing awareness about the liver diseases, and increased consumption of alcohol and improper diet. Furthermore, with the prevalence of liver disorders, governments and other not-for-profit organizations play a vital role in increasing awareness about liver diseases. Henceforth all these organizations support research and development for the prevention, promoting the understanding of liver-related diseases and treatment, and cure of liver diseases.

Liver Disease Market was US$ 16.21 Billion in 2021:

Regarding treatment type, the antiviral drugs segment is the largest market in 2021. This trend is likely to continue to grow during the forecast period, owing to the increased prevalence of viral liver diseases.

Based on Region, North America is the most significant market for Liver Disease Treatment:

In terms of region, North America leads the market owing to research and academic institutes conducting clinical trial studies in the region. Changing lifestyles, such as the growing consumption of alcohol and unhealthy diets, have also raised the incidences of liver disease. Additionally, growing patient awareness levels and introducing new products targeting unmet medical demands are projected to drive regional market growth over the coming year.

Impact of COVID-19 on Liver Disease Market:

The increasing number of COVID-19 cases has found liver disorder involvement. In COVID‐19, the cause of liver injury can be recognized by multiple factors, including virus‐induced hypoxia, systemic inflammation, hepatic congestion, and drug-induced liver disease.

In addition, COVID‐19 has been associated with liver‐related mortality and hepatic decompensation among patients with cirrhosis. Further, COVID‐19’s effect on healthcare resources has adversely affected the outcomes of patients with chronic liver disease and care delivery. Consequently, there has been a reduction in the diagnosis, treatment, and follow-up of patients with liver disease, negatively affecting the healthcare industry.

Competitive Landscape:

Various companies like Abbott Laboratories, Eli Lilly, Sanofi, Johnson & Johnson, Bristol Myers Squibb Co., Merck & Co. Inc., and Bayer AG are found advanced treatment drugs for liver diseases and investing in their R&D to develop innovative.

Renub Research latest report “Liver Disease Market, Forecast By Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteriods, Targeted Therapy, Chemotherapy), Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders and Others),End-User (Hospitals, Ambulatory Surgery Centers, Other),Region ( North America, Europe, Asia Pacific, LAMEA),Companies (Abbott Laboratories, Eli Lilly, Sanofi, Johnson & Johnson, Bristol Myers Squibb Co., Merck & Co. Inc., and Bayer AG)” provides a detailed analysis of Global Liver Disease Industry.

Treatment Type – Global Liver Disease Market has been covered from 7 viewpoints:

1. Antiviral Drugs
2. Immunosuppressants
3. Vaccines
4. Immunoglobulins
5. Corticosteriods
6. Targeted Therapy
7. Chemotherapy

Disease Type – Global Liver Disease Market has been covered from 6 viewpoints:

1. Hepatitis
2. Autoimmune Diseases
3. Non-alcoholic Fatty Liver Disease
4. Cancer
5. Genetic Disorders
6. Others

End Use – Global Liver Disease Market has been covered from 3 viewpoints:

1. Hospitals
2. Ambulatory Surgery Centers
3. Other

Region – Global Liver Disease Market has been covered from 4 viewpoints:

1. North America
2. Europe
3. Asia Pacific
4. LAMEA

Company Insights:

• Overview
• Initiatives/Recent Developments
• Financial Insight

Companies Covered:

1. Abbott Laboratories
2. Eli Lilly
3. Sanofi
4. Johnson & Johnson
5. Bristol Myers Squibb Co.
6. Merck & Co. Inc.
7. Bayer AG

Table of Contents

140 Pages
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Liver Disease Market
6. Market Share – Global Liver Disease Market
6.1 By Treatment Type
6.2 By Disease type
6.3 By End Use
6.4 By Region
7. Treatment Type – Global Liver Disease Market
7.1 Antiviral Drugs
7.2 Immunosuppressants
7.3 Vaccines
7.4 Immunoglobulins
7.5 Corticosteriods
7.6 Targeted Therapy
7.7 Chemotherapy
8. Disease Type – Global Liver Disease Market
8.1 Hepatitis
8.2 Autoimmune Diseases
8.3 Non-alcoholic Fatty Liver Disease
8.4 Cancer
8.5 Genetic Disorders
8.6 Others
9. End Use – Global Liver Disease Market
9.1 Hospitals
9.2 Ambulatory Surgery Centers
9.3 Other
10. Region – Global Liver Disease Market
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America, Middle East and Africa (LAMEA)
11. Company Analysis
11.1 Abbott Laboratories
11.1.1 Overview
11.1.2 Recent Development
11.1.3 Financial Insights
11.2 Eli Lilly
11.2.1 Overview
11.2.2 Recent Development
11.2.3 Financial Insights
11.3 Sanofi
11.3.1 Overview
11.3.2 Recent Development
11.3.3 Financial Insights
11.4 Johnson & Johnson
11.4.1 Overview
11.4.2 Recent Development
11.4.3 Financial Insights
11.5 Bristol Myers Squibb Co.
11.5.1 Overview
11.5.2 Recent Development
11.5.3 Financial Insights
11.6 Merck & Co. Inc.
11.6.1 Overview
11.6.2 Recent Development
11.6.3 Financial Insights
11.7 Bayer AG
11.7.1 Overview
11.7.2 Recent Development
11.7.3 Financial Insights
List of Figures:
Figure-01: Global – Liver Disease Market (Billion US$), 2016 – 2022
Figure-02: Global – Forecast for Liver Disease Market (Billion US$), 2023 – 2027
Figure-03: Treatment Type – Antiviral Drugs Market (Million US$), 2016 – 2022
Figure-04: Treatment Type – Forecast for Antiviral Drugs Market (Million US$), 2023 – 2027
Figure-05: Treatment Type – Immunosuppressants Market (Million US$), 2016 – 2022
Figure-06: Treatment Type – Forecast for Immunosuppressants Market (Million US$), 2023 – 2027
Figure-07: Treatment Type – Vaccines Market (Million US$), 2016 – 2022
Figure-08: Treatment Type – Forecast for Vaccines Market (Million US$), 2023 – 2027
Figure-09: Treatment Type – Immunoglobulins Market (Million US$), 2016 – 2022
Figure-10: Treatment Type – Forecast for Immunoglobulins Market (Million US$), 2023 – 2027
Figure-11: Treatment Type – Corticosteriods Market (Million US$), 2016 – 2022
Figure-12: Treatment Type – Forecast for Corticosteriods Market (Million US$), 2023 – 2027
Figure-13: Treatment Type – Targeted Therapy Market (Million US$), 2016 – 2022
Figure-14: Treatment Type – Forecast for Targeted Therapy Market (Million US$), 2023 – 2027
Figure-15: Treatment Type – Chemotherapy Market (Million US$), 2016 – 2022
Figure-16: Treatment Type – Forecast for Chemotherapy Market (Million US$), 2023 – 2027
Figure-17: Disease Type – Hepatitis Market (Million US$), 2016 – 2022
Figure-18: Disease Type – Forecast for Hepatitis Market (Million US$), 2023 – 2027
Figure-19: Disease Type – Autoimmune Diseases Market (Million US$), 2016 – 2022
Figure-20: Disease Type – Forecast for Autoimmune Diseases Market (Million US$), 2023 – 2027
Figure-21: Disease Type – Non-alcoholic Fatty Liver Disease Market (Million US$), 2016 – 2022
Figure-22: Disease Type – Forecast for Non-alcoholic Fatty Liver Disease Market (Million US$), 2023 – 2027
Figure-23: Disease Type – Cancer Market (Million US$), 2016 – 2022
Figure-24: Disease Type – Forecast for Cancer Market (Million US$), 2023 – 2027
Figure-25: Disease Type – Genetic Disorders Market (Million US$), 2016 – 2022
Figure-26: Disease Type – Forecast for Genetic Disorders Market (Million US$), 2023 – 2027
Figure-27: Disease Type – Others Market (Million US$), 2016 – 2022
Figure-28: Disease Type – Forecast for Others Market (Million US$), 2023 – 2027
Figure-29: End Use – Hospitals Market (Million US$), 2016 – 2022
Figure-30: End Use – Forecast for Hospitals Market (Million US$), 2023 – 2027
Figure-31: End Use – Ambulatory Surgery Centers Market (Million US$), 2016 – 2022
Figure-32: End Use – Forecast for Ambulatory Surgery Centers Market (Million US$), 2023 – 2027
Figure-33: End Use – Other Market (Million US$), 2016 – 2022
Figure-34: End Use – Forecast for Other Market (Million US$), 2023 – 2027
Figure-35: North America – Liver Disease Market (Million US$), 2016 – 2022
Figure-36: North America – Forecast for Liver Disease Market (Million US$), 2023 – 2027
Figure-37: Europe – Liver Disease Market (Million US$), 2016 – 2022
Figure-38: Europe – Forecast for Liver Disease Market (Million US$), 2023 – 2027
Figure-39: Asia Pacific – Liver Disease Market (Million US$), 2016 – 2022
Figure-40: Asia Pacific – Forecast for Liver Disease Market (Million US$), 2023 – 2027
Figure-41: Latin America, Middle East and Africa – Liver Disease Market (Million US$), 2016 – 2022
Figure-42: Latin America, Middle East and Africa – Forecast for Liver Disease Market (Million US$), 2023 – 2027
Figure-43: Abbott Laboratories – Global Revenue (Billion US$), 2016 – 2022
Figure-44: Abbott Laboratories – Forecast for Global Revenue (Billion US$), 2023 – 2027
Figure-45: Eli Lilly – Global Revenue (Billion US$), 2016 – 2022
Figure-46: Eli Lilly – Forecast for Global Revenue (Billion US$), 2023 – 2027
Figure-47: Sanofi – Global Revenue (Billion US$), 2016 – 2022
Figure-48: Sanofi – Forecast for Global Revenue (Billion US$), 2023 – 2027
Figure-49: Johnson & Johnson – Global Revenue (Billion US$), 2016 – 2022
Figure-50: Johnson & Johnson – Forecast for Global Revenue (Billion US$), 2023 – 2027
Figure-51: Bristol Myers Squibb Co. – Global Revenue (Billion US$), 2016 – 2022
Figure-52: Bristol Myers Squibb Co. – Forecast for Global Revenue (Billion US$), 2023 – 2027
Figure-53: Merck & Co. Inc. – Global Revenue (Billion US$), 2016 – 2022
Figure-54: Merck & Co. Inc. – Forecast for Global Revenue (Billion US$), 2023 – 2027
Figure-55: Bayer AG – Global Revenue (Billion US$), 2016 – 2022
Figure-56: Bayer AG – Forecast for Global Revenue (Billion US$), 2023 – 2027
List of Tables:
Table-01: Global – Liver Disease Market Share by Treatment Type (Percent), 2016 – 2022
Table-02: Global – Forecast for Liver Disease Market Share by Treatment Type (Percent), 2023 – 2027
Table-03: Global – Liver Disease Market Share by Disease Type (Percent), 2016 – 2022
Table-04: Global – Forecast for Liver Disease Market Share by Disease Type (Percent), 2023 – 2027
Table-05: Global – Liver Disease Market Share by End Use (Percent), 2016 – 2022
Table-06: Global – Forecast for Liver Disease Market Share by End Use (Percent), 2023 – 2027
Table-07: Global – Liver Disease Market Share by Region (Percent), 2016 – 2022
Table-08: Global – Forecast for Liver Disease Market Share by Region (Percent), 2023 – 2027

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us